Printer Friendly

ANI Pharmaceuticals launches Candesartan Hydrochlorothiazide Tablets.

M2 PHARMA-October 5, 2018-ANI Pharmaceuticals launches Candesartan Hydrochlorothiazide Tablets

(C)2018 M2 COMMUNICATIONS

ANI Pharmaceuticals Inc (Nasdaq: ANIP), an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals, yesterday announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg and 32mg/25mg, an authorized generic of Atacand HCT.

The product is indicated for the treatment of hypertension.

Arthur S Przybyl, ANI's president and CEO, said, 'We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT. This launch represents ANI's sixth generic new product introduction in 2018.'

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 5, 2018
Words:111
Previous Article:Kala Pharmaceuticals Prices Public Offering of 7.5m Shares of Common Stock.
Next Article:Wamberg Genomic Advisors names new managing director.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |